IMPORTANCE Laryngopharyngeal reflux (LPR) is thought to be a potential exacerbating factor in upper airway diseases.
L aryngopharyngeal reflux (LPR) is an extraesophageal manifestation of gastroesophageal reflux disease (GERD), which was first described as ulcers and granulomas of the larynx by Cherry and Margulies in 1968. 1 Studies carried out recently have demonstrated the reflux as a potential exacerbating factor in upper airway diseases. 2 Although 2 theories have been proposed, it is still not known whether there is a relationship between reflux and nasal diseases. [3] [4] [5] One of the theories is that acidic content reaching the upper airways triggers nasal congestion and inflammation. 3, 4 The second theory is about the esophageal-nasal reflex mechanism stimulated by vagal nerve response. This mechanism results in the congestion of nasal mucosa and a pathologic increase in nasal mucus secretion. 5 The purpose of this study was to evaluate the effect of LPR on the nasal airway and to determine the subsequent changes in symptoms and in nasal airway resistance after medical treatment.
Methods
We conducted a prospective observational clinical study. All investigations were performed in accordance with the guidelines regarding biomedical studies involving human subjects in the Declaration of Helsinki, and written informed consent was obtained from all participants before the study began. This study was approved by the Clinical Research Ethics Committee of Turgut Ozal University School of Medicine.
Participants
There were 2 groups in the study. In the study group, the patients had classic GERD symptoms such as heartburn and regurgitation. They underwent esophagogastroscopic examination by the same gastroenterologist. A total of 164 patients had lower esophageal sphincter dysfunction and grade B or C esophagitis according to the Los Angeles classification system. 6 These 164 patients were directed to the otorhinolaryngology department, where they underwent a complete otorhinolaryngologic examination.
The following 3 exclusion criteria were then applied: (1) presence of acute or chronic nasal infection, septal deviation, turbinate hypertrophy, allergic rhinitis, nasal polyps, or other mass lesions of the nasal cavity, as determined by means of flexible nasopharyngolaryngoscopic examination; (2) current use of intranasal corticosteroid, antihistamine, decongestant and/or systemic corticosteroid, proton pump inhibitor, or histamine H2 receptor antagonists; and (3) history of Nissen fundoplication surgery.
After the exclusion criteria were applied, the remaining 98 patients were examined by 2 otolaryngologists. The Reflux Symptom Index (RSI) ( Figure 1 ) and Reflux Finding Score (RFS) (Figure 2) proposed by Belafsky et al 7, 8 were used to identify the diagnosis of LPR. The remaining 50 patients with RFS greater than 7 and RSI greater than 13 were enrolled in the study group. The control group consisted of patients who were seen in the otorhinolaryngology clinic without any complaint about LPR (RFS <7.0 and RSI <13.0), without any history of nasal disease, and who did not use intranasal corticosteroids, antihistamines, decongestants and/or systemic corticosteroids, or antihistamines currently. The control group underwent flexible nasopharyngolaryngoscopic examination, and patients with a diagnosis of acute or chronic nasal infection, septal deviation, turbinate hypertrophy, allergic rhinitis, nasal polyps, or other mass lesions of nasal cavity were excluded ( Figure 3 ).
Study Design
All participants were asked to complete the Nasal Obstruction Symptom Evaluation (NOSE) Questionnaire, which has a 0 to 4 point scale (0, not a problem; 1, very mild problem; 2, moderate problem; 3, fairly bad problem; and 4, severe problem). The NOSE Questionnaire was used to evaluate the following symptoms: swelling or fullness in the nose, nasal congestion, difficulty in breathing through the nose; difficulty in sleeping; and inability to breathe comfortably through the nose during exercise or effort. 9 All patients in the study and control groups were examined by rhinomanometry (NR6 instrument, G M Instruments Ltd) to measure total nasal resistance (TNR). The rhinomanometry was calibrated according to the international standard committee's 2005 regulations. 10 Rhinomanometric measurement was fulfilled in a standard, active, anterior procedure, and the data were presented as nasal inspiratory resistances indirectly measured from the flow at a reference pressure of 150 Pa. Patients were held in a seated position and asked to breathe through their noses with their mouths closed. All the patients in the study group were advised on dietary modification and lifestyle changes to improve their conditions and prescribed oral antireflux proton pump inhibitor medication (pantoprazole, 40 mg) twice a day for 12 weeks.
All data about RSI, RFS, the NOSE Questionnaire, and TNR were collected before and after 12 weeks of proton pump inhibitor treatment.
Statistical Analysis
All statistical analyses were performed using the Statistical Package Program for the Social Sciences (version 15.0; SPSS Inc) software. Following the entry of patient data, all necessary diagnostic checks and corrections were performed. The conformity of the measured values with a normal distribution was examined graphically by the use of the Shapiro-Wilk test. Median
Key Points
Question Is laryngopharyngeal reflux associated with nasal resistance, and does pharmacologic therapy improve subjective and objective nasal findings?
Findings This case-control study of 100 adults (50 with laryngopharyngeal reflux, 50 controls) found that oral antireflux medication was associated with significant decreases in all parameters of the Nasal Obstruction Symptom Evaluation and Total Nasal Resistance values.
Meaning Laryngopharyngeal reflux has a negative effect on nasal resistance and nasal congestion; treatment may improve subjective and objective nasal findings.
Antireflux Medication and Laryngopharyngeal Reflux in Nasal Resistance
Original (minimum-maximum) values were used for groups that were not distributed normally. The Wilcoxon test was used to evaluate the dependent groups whereas the Mann-Whitney test was used to evaluate the independent groups. Median differences were analyzed by the independent samples Hodges-Lehman median difference method with 95% confidence interval.
Results
A total of 100 adults participated in the study. The LPR group consisted of 50 patients, 29 women (58%) and 21 men (42%) with a median age of 41.5 years (range, 18-64 years). The control group consisted of 50 patients, 27 women (54%) and 23 men (46%) with a median age of 38.5 years (range, 19-63 years).
There was no statistically significant difference between the age (difference, −2 years; 95% CI, −9 to 3 years) and sex distributions of the groups. The RSI, RFS, and NOSE Questionnaire results before and after treatment are reported in the Table. The RSI (difference, −11.0; 95% CI, −12.0 to −10.0), RFS (difference, −3.5; 95% CI, −4.0 to −3.5), and NOSE Questionnaire results (difference, −3.0; 95% CI, −3.5 to −2.5) were significantly lower than pretreatment values (Table) . Only 1 patient had a higher TNR value after treatment (before treatment, 0.12; after treatment, 0.13). The NOSE symptom score decreased in 47 patients, but 3 patients did not mention any change. A total of 43 patients (86%) had an RSI score less than 13 and 48 patients (96%) had an RFS score of less than 7.0 after treatment. The median TNR scores of the LPR group before treatment were significantly higher than those of the control group (difference, −0.77; 95% CI, −0.10 to −0.05), whereas there was no statistically significant difference between the median TNR scores of the LPR group after treatment and the control group (difference, 0.01; 95% CI, −0.01 to 0.03) (Table) . The median NOSE scores of the LPR group before treatment were significantly higher than those of the control group (difference, −2.0; 95% CI, −3.0 to −1.0). The median NOSE scores of the LPR group were significantly higher before than after treatment (difference, −3.0; 95% CI, −3.5 to −2.5) (Table) .
Discussion
Gastroesophageal reflux disease is considered to be an important cause of LPR that is associated with laryngeal inflammation. 11 The most common symptoms of this condition presented in ear, nose, and throat clinics are hoarseness, throat pain, and sensation of a lump in the throat 11 ; however, numerous investigations have postulated that inflammation is not limited to the laryngeal mucosa. 12 Moreover, some researchers have expressed that LPR was related to the pathogenesis of chronic rhinosinusitis, middle ear effusion, postnasal drip, halitosis, and smelling and tasting problems. 12, 13 The aim of this study was to evaluate the nasal resistance and nasal symptoms in patients with LPR. To our knowledge, this is the first study investigating the effect of LPR on nasal resistance. In this study, we observed higher nasal resistance and NOSE scores in patients with LPR before treatment. Furthermore, Bozec et al 14 also observed higher nasal resistance scores, increased visual analog scale scores of nasal obstruction, and posterior rhinorrhea in 20 patients with GERD. In our study, we used a larger sample size of 50 patients with LPR, and we used the NOSE questionnaire, which is a specific and reliable tool to evaluate nasal obstruction in adults. 
Because we excluded the patients with nasal obstruction, the median NOSE score of the patients in the study group before treatment was slightly different from the control group, but we observed significant improvement in NOSE scores after treatment.
Most of the literature in this area has investigated the relationship between chronic rhinosinusitis and reflux; Holmes et al 15(pp1-54) proposed a connection between sinonasal disease and gastric hypersecretion. DiBaise et al 16 observed abnormal pH meter results in 78% of patients with chronic rhinosinusitis. Additional evidence came from the 20-Item Sino-Nasal Outcome Test (SNOT-20), which was administered to 77 patients with proven GERD and controls.
The authors reported that the mean SNOT-20 score was 22.1 in the study group and 9.4 in the control group. 17 Recent studies have assessed pharyngeal and nasopharyngeal pH monitoring and pepsin detection in mucosal secretions to show the direct exposure of acidic content above the laryngeal upper esophageal sphincter. 3, 18, 19 In a study of 20 patients with chronic rhinosinusitis, 19 had a positive pharyngeal pH meter result, and 17 had positive nasopharyngeal pH meter results. Also, pepsin levels in nasal lavage fluid were positive in 5 patients. 18 Similarly, standard pH meter probes lose contact with mucosa and cause artifacts that make previous study results controversial. They used a circumferential 4-channel pH probe that was less subject to artifact and demonstrated that direct reflux into the nasopharynx was a rare event. 5 Wong et al 5 performed an acid infusion challenge test on 10 healthy volunteers. They found no abnormal pH meter results in the nasopharynx by the use of a circumferential 4-channel pH probe, but there was a decrease in nasal peak flow, significantly greater concentration of fucose, and an increase in visual analog scale score. 5 The authors proposed that higher acid concentrations in the lower esophagus trigger an esophageal-nasal reflex mechanism that causes a decrease in nasal airflow and mucociliary clearance rate. 5 Although the methods used in the study of Wong et al 5 were objective, the number of cases was limited. There are some other studies that support the vagal reflex mechanism theory. Lodi et al 20 and Harding et al 21 showed that patients with asthma and GERD had an increased vagal response compared with that of patients with asthma alone. Moreover, Delehaye et al 22 found a statistically significant prolongation of the mucociliary transport time in 74% of patients with erosive esophagitis. Interestingly, the patients whose mucociliary transport time was not prolonged exhibited extraesophageal reflux. The authors concluded that the erosion in the distal esophagus triggered the vagal reflex mechanism.
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Limitations
In our study, we observed higher nasal resistance in the LPR group. The patients included in the study had esophagitis, so vagal reflex activation may be the possible cause of the pathophysiologic mechanism as Delehaye et al 22 reported.
Because we did not measure pH in this study, we could not rule out direct acid exposure. Because of this limitation, we were not able to make an exact comment on pathophysiological processes. In our opinion, it could be possible that both direct acid exposure and vagal reflex activation were the exacerbating factors. There are currently few reported studies seeking to clarify the effects of GERD and LPR on the upper respiratory tract. Therefore, additional clinical trials are needed to elucidate the pathophysiological processes that contribute to these respiratory changes.
Conclusions
Laryngopharyngeal reflux may play a role in the formation of nasal disease; however, there is no clear evidence to explain the mechanism of disease. In this study, we found that LPR had a negative effect on nasal resistance and nasal congestion. Laryngopharyngeal reflux treatment can improve subjective and objective nasal findings. Gastroesophageal reflux disease (GERD) is highly prevalent, and its most common symptoms, including heartburn and regurgitation, may be present in up to 45% of the population. 1 Laryngopharyngeal reflux (LPR) is an extraesophageal manifestation of GERD that may be present in up to 10% of patients presenting for ambulatory otolaryngology visits. 2 Typical symptoms that have been attributed to LPR include globus sensation, laryngospasm, throat clearing, and hoarseness. Moreover, it has been postulated that mucosal inflammation due to LPR may extend beyond the larynx and oropharynx to the nasopharynx and nasal cavity, contributing to the pathogenesis of sinonasal diseases. For example, an association between chronic rhinosinusitis (CRS) and GERD has been shown through epidemiologic studies that have found high rates of pharyngeal reflux in CRS, 3 as well as the finding of digestive enzymes in the nasal secretions of patients with CRS. 4 Despite this, few studies have objectively examined the effect of treatment of LPR on sinonasal symptoms. In this issue of JAMA Otolaryngology-Head & Neck Surgery, Dagli and colleagues 5 report their experience with the symptom of nasal obstruction in patients with LPR and report how the use of a proton pump inhibitor (PPI) to treat these patients' LPR affects concomitant nasal obstruction. The authors conducted a prospective observational clinical study in which 50 patients with confirmed esophagitis and symptoms of LPR, making up the study group, were treated with a PPI for 12 consecutive weeks and no other treatment for nasal obstruction, such as intranasal corticosteroids, was given. The study group had no other evidence of sinonasal disease, such as CRS or allergic rhinitis, and was compared with a control group, consisting of 50 patients with no evidence of LPR or other sinonasal diseases who had no symptoms of nasal obstruction. Pretreatment assessment of the LPR group included a subjective measurement of nasal congestion with the Nasal Obstruction Symptom Evaluation (NOSE) instrument and an objective measurement of total nasal resistance (TNR) using rhinomanometry. Compared with the control group, the LPR group had a significantly higher median NOSE score and TNR before treatment with a PPI. After 12 weeks of treatment with a PPI, not only did the study group demonstrate significantly lower NOSE scores and TNR, but the posttreatment NOSE scores and TNR of the study group also normalized to be no different than what was found in the control group. This is the first study to prospectively study the impact of LPR treatment on subjective and objective measures of nasal obstruction, and the results provide novel evidence for the relationship of LPR to sinonasal symptoms. The finding that treatment of LPR with a PPI alone-and no treatment directed at nasal symptoms-was sufficient to reduce nasal obstruction in patients with LPR suggests that LPR at the very least has the ability to contribute to nasal symptoms. Moreover, the findings of this study have important implications for the treatment of patients presenting with nasal obstruction. Dagli and colleagues 5 show that in patients with nasal obstruction, LPR may have a causative role and that in these patients, comorbid LPR should be investigated for and treated with a PPI as a component of management for nasal obstruction. This prospective study by Dagli and colleagues 5 provides the strongest evidence to date for a causative role for LPR in nasal obstruction symptoms and thus provides novel insights for the clinical investigation and potential treatment of patients presenting with nasal obstruction. These findings should also motivate further studies in the form of a doubleblind randomized clinical trial of PPIs for the treatment of nasal obstruction in patients with LPR given the lack of randomization in this study. Because the study patients were recruited on the basis of LPR rather than complaints of nasal obstructive symptoms, an interventional study designed for the specific treatment of nasal obstruction in patients with LPR may best determine the efficacy of PPIs. Moreover, the authors excluded patients from this study who might have any sinonasal etiology-such as chronic rhinosinusitis, allergic rhinitis, inferior turbinate hypertrophy, or septal deviation-for nasal obstruction. Future investigation will need to identify whether the results of this study are generally applicable to all patients with LPR or whether there are particular subsets of patients with LPR who experience the greatest reduction in nasal obstructive symptoms after treatment with a PPI. For example, how would comorbid allergy affect the efficacy of LPR treatment in reducing nasal obstruction, and for those with seasonal allergies, does the time of the year affect the efficacy of 
